- In response to a recent New York Times article, Cellceutix Corporation of Beverly said it is already testing a P53 drug called Kevetrin in clinical trials at Dana-Farber.
- At the AACR Annual Meeting 2013, George Demetri, MD, reported in a study that a simple blood sample revealed more cancer-causing mutations than a tumor biopsy alone.
- Dr. Robert Soiffer explains how donating bone marrow and stem cells can help save lives, and describes the process for joining a donor registry.
- People recently gathered at St. James Armenian Church in Watertown to support Sarkis Chekijian, who is running the Boston Marathon to raise research funds for Dana-Farber.
- Drs. Harold Burstein, Loren Walensky and Mehra Golshan, Dana-Farber faculty members who are married to physicians, were featured in a profile on married couples who are both physicians or scientists.
- Dana-Farber researchers, including Dr. Rameen Beroukhim, have identified DNA mutations that appear to drive about 15 percent of meningiomas, a finding that could lead to the first effective drug treatments for these brain tumors.
Tags: TargetedTherapy, BrainTumors
- Cambridge-based Foundation Medicine is bringing high-tech tools to the battle against cancer. Founded in 2009 by leaders in genome technology including Dana-Farber, the company is analyzing patients' tumors for the entire coding sequence of 200-plus genes known to be altered in human cancers.
- Breast cancer surgeons have been having an ongoing discussion on how much tissue to breast tissue to remove when removing a tumor. Dr. Mehra Golshan said that with ductal carcinoma in situ (DCIS), a very treatable, early stage cancer, smaller margins are acceptable and appropriate.
Tags: BreastCancer, Surgery
Showing 21-30 of 216 items